Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6189503 | 0.93 | MCHR1 (0.74) | MCHR1KCNH2ACHEHTR1AHTR7 | |
| Trifluoroacetic Acid SCHEMBL6314023 | 0.93 | MCHR1 (0.67) | MCHR1KCNH2ACHE | |
| SCHEMBL6188949 | 0.92 | MCHR1 (0.73) | MCHR1KCNH2ACHEHTR1AHTR7 | |
| SCHEMBL6188162 | 0.91 | MCHR1 (0.80) | MCHR1KCNH2ACHE | |
| SCHEMBL6186090 | 0.91 | MCHR1 (0.76) | MCHR1KCNH2ACHE | |
| SCHEMBL6187459 | 0.89 | MCHR1 (0.76) | MCHR1KCNH2ACHE | |
| SCHEMBL6188586 | 0.89 | MCHR1 (0.76) | MCHR1KCNH2ACHE | |
| SCHEMBL6186832 | 0.88 | MCHR1 (0.72) | MCHR1KCNH2ACHE | |
| SCHEMBL6238232 | 0.88 | MCHR1 (0.77) | MCHR1KCNH2ACHE | |
| SCHEMBL6187535 | 0.88 | MCHR1 (0.75) | MCHR1KCNH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | claimed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 2839/4885ACHE 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.